Generic Name: vedolizumab
Brand Name: Entyvio
Manufacturer: Takeda Canada Inc.
Indications: Crohn’s disease
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNF antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule C
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input open||May 05, 2020|
|Call for patient input closed||June 24, 2020|
- Patient input submission received from Crohnâs and Colitis Canada and Gastrointestinal Society
|Submission received||July 23, 2020|
|Submission accepted||August 07, 2020|
|Review initiated||August 10, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||October 23, 2020|
|Deadline for sponsors comments||November 03, 2020|
|CADTH responses on draft review report(s) provided to sponsor||November 27, 2020|
|Expert committee meeting (initial)||December 09, 2020|
|Draft recommendation issued||December 21, 2020|
December 23, 2020